IPH (IPH) News
Follow IPH (IPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Sobi and Innate partnership becomes effective after closing conditions
Sobi and Innate Pharma said their previously announced strategic partnership is now effective following completion of closing conditions.
MNA | Sep 17, 2026, 03:30 AM UTC
M
Innate and Sobi partnership becomes effective after closing conditions
Innate Pharma said its previously announced strategic partnership with Sobi is now effective after applicable antitrust waiting periods expired and other closing conditions were completed.
MNA | Sep 16, 2026, 08:00 PM UTC
L
IPH: Key late-stage data and partnerships position the pipeline for major milestones and growth
The discussion highlighted a strategic focus on three core assets, with key partnerships supporting late-stage development and commercialization. Upcoming data from IPH4502 and PACIFIC-9 are major catalysts, while innova
NEWS | Sep 14, 2026, 09:41 PM UTC
L
IPH: Key assets advance toward pivotal data and regulatory milestones, driven by strategic partnerships
The discussion highlighted a focused strategy on three core assets, with major milestones expected for lacutamab, IPH4502, and monalizumab by year-end. Strategic partnerships, innovative ADC development, and upcoming piv
NEWS | Sep 14, 2026, 09:14 PM UTC
L
Innate Pharma to host Sep 17 call for first-half 2026 results
Innate Pharma will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT to provide a business update for first half of 2026.
EQUITY | Sep 10, 2026, 05:00 AM UTC
L
Insider Trades: 23 ASX 200 directors bought and sold these stocks last week
Welcome back to the Insider Trades series — a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 31 August and 3 September. Directors have
EQUITY | Sep 07, 2026, 04:56 AM UTC
L
Innate Pharma executive team to take part in H.C. Wainwright conference
Innate Pharma SA said members of its executive team will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 02, 2026, 05:00 AM UTC